Financial Consequences of Suboptimal Drug Therapy in Neuropathic Pain Treatment

Neuropathic pain (NeP) is a complex and chronic pain condition arising from damage or disease affecting the somatosensory nervous system. Unlike nociceptive pain, which is due to injury or threat of injury to non-neural tissue, NeP results from direct insult to the neural pathways responsible for pain processing. According to the International Association for the Study of Pain (IASP), NeP is defined as pain caused by a lesion or disease of the somatosensory nervous system. This condition encompasses a wide range of clinical disorders, including diabetic peripheral neuropathy, trigeminal neuralgia, postherpetic neuralgia, post-stroke pain, complex regional pain syndrome, and neuropathic back and leg pain. Clinically, neuropathic pain often presents with characteristic symptoms such as burning, shooting, or electric shock-like sensations, frequently accompanied by sensory abnormalities including hyperalgesia (increased sensitivity to pain) and allodynia (pain from stimuli that are normally non-painful). Beyond its physiological impact, NeP significantly impairs psychological well-being and quality of life. Many patients suffer from chronic, persistent pain that disrupts daily functioning, emotional health, and productivity. Understanding the pathophysiology and clinical manifestations of neuropathic pain is crucial for optimizing management strategies. Despite advances in pharmacological and non-pharmacological treatments, managing NeP remains challenging due to its complex nature and variable patient response. The economic burden resulting from ineffective or irrational prescribing practices further complicates care delivery, emphasizing the need for evidence-based therapeutic approaches. This paper aims to review the clinical features of neuropathic pain and highlight the importance of appropriate pharmacological interventions to improve patient outcomes and reduce economic strain on healthcare systems